| Feature | Perfect competition | Monopoly |
|---|
| Number of firms | Many (small) | One (large) |
| Products | Identical | Unique |
| Entry/exit | Free | Blocked by barriers |
| Information | Perfect | Limited |
| Price | Set by market | Set by monopolist |
| Firms | Price takers | Price makers |
| Long-run profit | Zero (normal) | Above-normal (super-normal) |
| Output | High | Restricted |
| Allocative efficiency | Yes | No |
| Consumer welfare | Higher | Lower |
The deadweight loss of monopoly. Because monopoly restricts output below the competitive level, society loses some valuable trades that would have happened in competition. This loss is 'deadweight' — no-one gains from it.
The R&D defence of monopoly. Patent monopolies in pharmaceuticals, software, and biotech are TEMPORARY monopolies (typically 20 years) granted to reward R&D investment. Without the patent monopoly, firms would have less incentive to develop new drugs. The trade-off: short-run high prices for long-run innovation.
Where do REAL markets sit between PC and monopoly?
Most real markets are somewhere in between — called monopolistic competition (many firms with differentiated products, like restaurants) or oligopoly (a few large firms dominating, like supermarkets or airlines). 0455 only covers the two extremes, but real-market analysis usually involves understanding intermediate structures.
Cambridge tip. Mark schemes for "compare the two structures" expect 4-5 dimensions covered (price, output, choice, efficiency, profit). Top-band answers add nuance — acknowledging that PC is theoretical and monopoly has some defences.